Runs a multi-specialty hospital together with a medical education business, with the healthcare segment accounting for almost all of revenue. In FY26 the healthcare segment generated ₹1,470.25 cr of revenue and the education segment brought in ₹115.39 cr, with consolidated segment EBIT of ₹337.61 cr on the ₹1,470.25 cr line. The hospital operates large physical infrastructure — a Neuro Sciences block inaugurated at a cost of ₹120 cr, and a 300-bed Paediatric Hospital approved by the board — and employs 5,527 permanent employees plus 699 permanent workers. Materials and consumables form the largest cost line at 28.3% of revenue, followed by employee costs at 19.3% and other operating expenses at 24.7%, with capex at 15.9% of revenue pointing to ongoing capacity expansion. The board has approved the divestment of the Allied Health Sciences courses division to a related-party trust for ₹84.54 lakhs to focus on core medical education programmes. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Healthcare services, Education. Asset-heavy hospital services with a smaller medical education arm
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 906 | 1,019 | 1,220 | 1,371 | 1,586 |
| EBITDA (ex other income) | 258 | 267 | 342 | 386 | 439 |
| margin % | 28.4 | 26.2 | 28.0 | 28.1 | 27.7 |
| Owners' profit | 104 | 116 | 180 | 209 | 244 |
| EPS, as reported (₹) | 95.28 | 105.80 | 164.25 | 190.95 | 223.41 |
| ROE % · ROCE % | 17.1 · 15.6 | 16.1 · 15.5 | 20.2 · 21.9 | 19.2 · 20.3 | 18.5 · 20.6 |
| Debt / equity (x) | 0.84 | 0.66 | 0.31 | 0.35 | 0.28 |
| Cash from operations | 263 | 263 | 344 | 353 | 362 |
| Capex | (99) | (127) | (138) | (353) | (252) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 315 | 344 | 355 | 357 | 374 | 392 | 407 | 414 |
| Profit before tax | 61 | 67 | 75 | 74 | 76 | 78 | 87 | 84 |
| Net profit | 46 | 51 | 58 | 55 | 57 | 59 | 65 | 63 |
| EPS (₹) | 41.81 | 46.32 | 52.83 | 49.99 | 52.30 | 53.79 | 59.42 | 57.90 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Healthcare | 1,471 | 92.7 |
| Education | 115 | 7.3 |
| Total, before eliminations | 1,587 | 100.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 27.8 | 28.4 | 127 of 261 | 52% |
| P/B | 5.2 | 3.4 | 160 of 238 | 33% |
| ROCE | 18.7 | 10.4 | 53 of 276 | 81% |
| ROE | 18.5 | 9.6 | 37 of 248 | 85% |
| Debt / Equity |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 27 Aug 2026 · KMCH 40th AGM: All 4 resolutions passed, including dividend approval | board shareholder meetings | low | — | — |
| 26 Aug 2026 · 40th AGM concluded via video conferencing; voting results pending | board shareholder meetings | low | — | — |
| 21 Aug 2026 · Postal ballot notice published in newspapers, e-voting from 21 Aug to 19 Sep 2026 | compliance | minimal | — | — |
| 20 Aug 2026 · Postal ballot to elevate Dr. Arun N Palaniswami as Joint Managing Director | management changes | high | — | — |
| 10 Aug 2026 · KMCH Q1 FY27 results: revenue up 15% YoY, PAT up 21% YoY | compliance | minimal | — | — |
| 7 Aug 2026 · KMCH Q1 FY27 net profit up 20.7 percent YoY; JMD re-designation approved | management changes | medium | — | — |
| 7 Aug 2026 · Board reconstitutes Corporate Social Responsibility Committee | management changes | low | — | — |
| 7 Aug 2026 · Dr Arun N Palaniswami redesignated as Joint Managing Director | management changes | medium | — | — |
| 7 Aug 2026 · Q1 FY27 results: Revenue up 15% YoY to Rs 430.9 cr, PAT rises 21% to Rs 69.1 cr | results | high | — | — |
| 30 Jul 2026 · KMCH files copies of newspaper ads for 40th AGM notice | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 0.3 |
| 0.1 |
| 172 of 248 |
| 31% |
| EBITDA margin | 28.8 | 19.1 | 63 of 239 | 74% |
| Revenue growth | 15.9 | 16.6 | 124 of 237 | 48% |
| Profit growth | 15.8 | 23.7 | 125 of 230 | 46% |
| Market cap | 6790 | 583 | 73 of 277 | 74% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
